Strategies aimed at blocking IL-33 or modulating its downstream effects hold significant therapeutic potential for managing and potentially preventing the progression of respiratory diseases characterized by type 2 inflammation, such as asthma, COPD, and allergic rhinitis. This evidence concerns the gene IL33 and chronic obstructive pulmonary disease.